Business Development as a Service

The BD infrastructure
your biotech deserves.

You lead the deal. We give you the firepower. CartaOS equips your CEO and Head of BD with deal benchmarking, partner intelligence, negotiation preparation, and due diligence support.

$252B
in biopharma licensing partnerships in 2025
J.P. Morgan Q4 2025 Report
$138B
in biopharma M&A across 129 deals
J.P. Morgan Q4 2025 Report
60%
of total deal value from partnerships
Blue Matter Consulting, 2025
2/3
of Phase 3 compounds from biotechs
BIO / PMC

If you are waiting for clinical data to start thinking about BD, you are already behind.

Most biotech CEOs begin building the partnering narrative after data lands. But by then, precedents have already been set. Partner landscapes have shifted. The other side of the table has had months of internal alignment while you are only getting started.

At most clinical-stage biotechs, the CEO, CFO, and a single Head of BD carry the entire deal. They do not have analysts. They do not have a deal team. The pharma company on the other side does.

Your CBO and Head of BD stay in the driver's seat.
CartaOS does not replace your leadership's judgment or their relationships. We provide the analytical infrastructure and deal intelligence behind them so that when they walk into a negotiation, they walk in with the same depth of information as the other side of the table.

What we do for you

Six technology-enabled services powered by proprietary predictive models and network science. Delivered as outcomes, not tools.

📊

Deal Benchmarking

Comparable transactions mapped against your asset. Upfronts, milestones, royalties, and deal structures.

Replaces 3-4 weeks of analyst work
🎯

Partner Identification

Pharma companies scored by strategic fit, pipeline gaps, and deal history. A strategic map, not a list.

Replaces network-only sourcing
📋

Negotiation Intelligence

Term ranges, precedent clauses, leverage points. Know where you sit vs. market and where to push.

Replaces weeks of CFO modeling
📝

Term Sheet Drafting

Commercial terms benchmarked against precedents. Flagged clauses where terms deviate from market norms.

Benchmarked against market
🔍

Due Diligence Preparation

DD question lists, data room structuring, response preparation. Ready before partners ask.

Anticipate partner questions
🤝

Embedded Team Support

Direct connection with your CEO, CBO, or Head of BD. 24/7 continuous support throughout the deal.

Your team leads, we deliver
Technology-Enabled Services

The intelligence layer behind every deal.

Deal-ready deliverables for your team and your advisors, powered by proprietary predictive models and network science.

🧠

Predictive Deal Models

Proprietary models that predict deal valuations, optimal term structures, and partnership probability, all customised to your specific asset and competitive landscape.

Most deal benchmarking today relies on a handful of precedents recalled from experience. CartaOS analyses thousands of structured transactions to show you exactly where your deal sits and where it should.
🔗

Network Science

We map the entire biopharma partnering ecosystem as a knowledge graph connecting companies, assets, deal histories, pipeline gaps, and strategic relationships.

Partner identification has traditionally been limited to existing networks. CartaOS maps the full partnering ecosystem and surfaces strategic fits based on structural patterns across thousands of deals, including partners your network would never reach.
📋

Generative Deal Intelligence

Our AI generates finished deliverables including benchmarking reports, negotiation briefs, due diligence question lists, and term sheet drafts, all contextualised for your specific transaction.

Deal preparation has always been manual, time-intensive, and static once delivered. CartaOS generates the same deliverables in hours and keeps them updated live as your deal evolves.
From one BD professional to another.

I have been on both sides of the deal table. The biggest gap in biotech partnering is not talent or relationships. It is infrastructure. The analytical depth, the structured deal data, the benchmarking. It takes years and dedicated teams to build. Most biotech deal teams simply do not have the time or resources to assemble that foundation while also running clinical programs and raising capital. CartaOS closes that gap by giving the people who make the decisions the analytical depth they deserve. That is the difference between negotiating and guessing.

🔒GDPR compliant
🛡️Enterprise security
🧠Proprietary models
🕐24/7 support

Built for the people who make deals happen.

Whether you advise on transactions or lead them, CartaOS provides the analytical depth to do it better.

👥

Advisory firms and consultancies

Amplify the value you already deliver. CartaOS gives your partners deeper benchmarking, faster turnaround, and richer deal intelligence to bring to every client engagement. Co-branded. Seamless.

Explore the partnership →
🧬

Biotech CEOs and BD teams

You have the science and the relationships. Whether you work with advisors or run BD in-house, CartaOS gives your team the deal infrastructure to walk into every room prepared.

Get started →
Anastasios Mastroanastasiou, Founder and CEO of CartaOS

"I watched biotech teams with transformative science walk into negotiations without the full picture. Not because their drugs were not extraordinary, but because they simply could not see the full deal landscape."

I build CartaOS to change that.

Anastasios Mastroanastasiou

Founder and CEO, CartaOS

Former BD and Licensing Due Diligence Lead at BioNTech SE. Transactions over $1B. Educated at Karolinska Institutet and Stockholm School of Economics. Research at Harvard Medical School and KAUST.

Your science deserves a deal team that matches it.

Tell us about your asset. We arm your BD team with everything they need.

How it works

You stay in the driver's seat. We arm your team with everything they need.

Step 01

Tell us about your asset

Therapeutic area, development stage, modality, target geographies, deal objectives.

Step 02

We connect with your team

CartaOS integrates with your CEO, CBO, or Head of BD. 24/7 support. GDPR compliant. Models customised to your deal.

Step 03

Your team gets the full package

Benchmarking, partner shortlist, negotiation strategy, DD prep, term sheet, and embedded support. Updated continuously.

See it in action

Walk through a live example.

What your team actually gets

30-person biotech. One Head of BD. No deal team. Here is the full package.

NovaBio: Phase II bispecific antibody in NSCLC

CEO and Head of BD need a pharma partner and need to negotiate from strength. CartaOS arms their team.

OncologyBispecific AbPhase IIOut-License
📊 Deal BenchmarkingDeliverable 1
DealUpfrontMiles.Roy.
Amgen/Xencor$100M$1.3BTiered
NovaBio$80-150M$1.2-1.8B10-15%
AZ/Daiichi$1.35B$5.6B20s%
Merck/Kelun$175M$9.3BTiered
🎯 Partner ShortlistDeliverable 2
94
AstraZeneca
Bispecific pipeline, NSCLC focus
91
Roche
IO franchise, co-dev history
87
Merck KGaA
NSCLC gap, global
79
Gilead
Building oncology portfolio
📋 Negotiation IntelligenceDeliverable 3
Upfront$80-150M
Dev milestones$400-600M
Royalties10-15%
Leverage insight
Phase II bispecifics with differentiated MOA command 15-25% upfront premiums with multiple bidders.
📝 Draft Term SheetDeliverable 4
Upfront$120M
Dev milestones$500M
Royalties12% tiered to 16%
Opt-in50/50 US Above market. Flag.
DiligencePh III in 18 months

This is what your team gets.

For your asset. Your deal. Your timeline.